Aragen Bioscience, Inc. and CEVEC Sign License Agreement for Human CAP® and CAP-TTM Technology

(PresseBox) ( Cologne, Germany, )
CEVEC Pharmaceuticals ("CEVEC"), the developer of a novel human expression system derived from amniocytes, and Aragen Bioscience, Inc. ("Aragen Bioscience"), a California based contract research and development organization, announced today the signing of a strategic license agreement. This license enables Aragen Bioscience to offer its clients custom recombinant human cell lines expressing biotherapeutic proteins and antibodies as well as the transient and stable production of preclinical and clinical grade material.

The transient CAP-T TM protein production technology is based on CAP® cells, an immortalized cell line for stable protein production developed by CEVEC. These nontumor origin cell lines exhibit high protein expression, have been adapted to serumfree suspension culture and show posttranslational modifications that are humanlike, including authentic human glycosylation patterns.

The collaboration couples CEVEC's novel and proprietary CAP and CAP-T expression systems and cell lines with Aragen Bioscience's vast experience in cell line and process development to provide biotechnology and biopharmaceutical companies worldwide the opportunity to utilize Aragen's services to gain access to CEVEC's technology and quickly obtain high quality preclinical and clinical grade product generated from stable as well as transiently transfected cell lines.

"We are very proud to win Aragen as an experienced and trusted partner to offer our CAP Technology to a broader audience in the Biotechnology and Pharma sector" stated Wolfgang Kintzel, CCO of CEVEC. "Our human amniocyte derived cells offer significant advantages when it comes to complex protein production and we're excited that Aragen has chosen our technology as a valuable addition to their existing service offerings. The signing of this contract also underlines the growing recognition our technology is receiving in the Life Sciences arena."

Rick Srigley, CEO of Aragen Bioscience said: "We are very excited about the potential of CEVEC's CAP and CAP-T technology. We believe that human cells will be a superior production system for a variety of complex proteins. CEVEC's technology is a valuable addition to our existing expression portfolio and will enable our customers to pursue new directions for proteins that were difficult to express in the past or did not show satisfactory posttranslational modifications."

About Aragen Bioscience, Inc. - www.aragenbio.com

Aragen Bioscience, Inc. is a contract research and development organization in Morgan Hill, California. Aragen specializes in recombinant cell line and hybridoma development, cell culture and protein purification process development and protein production, primary and immortalized cellbased assays, in vivo models of human disease and custom immunological services.
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to service@pressebox.de.